Trials / Recruiting
RecruitingNCT07283263
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First-in-Human Study Evaluating Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered BMS-986521 in Healthy Adult Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 106 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-985521 | Specified dose on specified days. |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2025-12-23
- Primary completion
- 2026-11-17
- Completion
- 2026-11-17
- First posted
- 2025-12-15
- Last updated
- 2026-01-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07283263. Inclusion in this directory is not an endorsement.